Presentation. March 23, 2006

Size: px

Start display at page:

Download "Presentation. March 23, 2006"

Hector Fletcher
7 years ago
Views:

1 Presentation March 23, 2006

2 The breakthrough Imagine detecting breast cancer and Alzheimer s disease from just a single drop of blood! Our proven disease fingerprinting method makes it possible

3 Concept DiaGenic's unique concept The primarily diseased part of the body eg breast, brain, lung - is not the only part responding to a disease. The disease also leaves a unique fingerprint in other parts of the body. These fingerprint responses can be measured through gene expression patterns on microarray chips.

4 Confirmation of DiaGenic s Concept: Several published works now demonstrate the use of peripheral blood as clinical sample for detecting diseases by use of gene expression Alzheimer s disease Multiple Sclerosis Schizophrenia Acute Ischemic Stroke Pulmonary Arterial Hypertension Heart Failure Allergy Other diseases like: renal disease Asthma stress and depression These works enables new US patent applications for several diseases in addition to Alzheimer s and cancer. Important potential for future growth.

5 Generic approach to gene signature discovery *Whole Genome Array WGA* 1000 Custom Microarrays No of transcripts to be analysed ABI TaqMan / Low Density Arrays Product development Patients sample

6 Development partnering model US patents Discovery Phase Prototype Development Design Verification Design Validation Regulatory/ Analyte Specific Reagents Product Launch DiaGenic Partner

7 We will provide the missing link - applications Technology Applications Sales and Marketing + Labcorp, Quest, a.o.

8 The Technology is ready and waiting Amplichip P450 Custom array

9 Your security - Strong IP position USA Europe First patent granted First patent granted DiaGenic has an active patent strategy to expand and ringfence its intellectual property rights

Finance Number of shares: 39.2 mill Share price March 23: NOK 9,70 Market cap: NOK 380 million Number of shares traded 2005: 60 million Burn rate approx.

10 Finance Number of shares: 39.2 mill Share price March 23: NOK 9,70 Market cap: NOK 380 million Number of shares traded 2005: 60 million Burn rate approx. NOK 2,0 million/month Private placement 3,5 million shares: NOK 33 mill Increasing attention from international investors DiaGenic share price development

11 Private Placement March 16, 2006 A total of 3,5 mill new shares and resale of 0,5 mill shares Transactions managed by DnB NOR Markets and ABG Sundal Collier Allocation to 35 professional investors: Approx. 25% allocated to International institutional investors (3. AP Fonden, Julius Baer Fund, Nordea) Approx. 25% to Norwegian institutional investors (Nordea Fondene, Holberg Fondene, Danske Fond, DnB NOR Fondene, Borea)

12 Shareholders 8,2% SHARMA PRAVEEN Founder 7,5% LØNNEBORG ANDERS Founder 5,9% NORDEA FONDENE (Norway) Increased PP Mar06 5,1% A/S SKARV From merger (2004) 4,6% 3. AP FONDEN (Life Science Fund) (Sweden) New (Nov. 2005)+ PP Mar06 4,6% INVESTOR VENTURE I KS (to be distributed to owners) VC (2000) 4,5% HOLBERG FONDENE Increased Nov PP Mar06 3,2% SÆTERØY HÅKON + INVESTOR CORPORATE AS Chairman (increased 2005 and 2006) 3,0% JULIUS BÄR Small Cap Fund (Switzerland) PP (April 2005) + PP Mar06 2,6% NORDEA LIV (Norway) 2001/2002 1,4% SKAGEN VEKST PP (April 2005) 1,4% DANSKE FUND PP (April 2005)+PP Mar 06 1,3% AMFIBIEN AS New (2005) 1,3% SANDEN AS From merger (2004) 0,9% STOREBRAND FOND PP (April 2005) + 45% among a total of approx OTHER SHAREHOLDERS

13 Organisation SHARMA, PRAVEEN LÖNNEBORG, ANDERS CHRISTIANSEN, DAG SÆTERØY, HÅKON Technical Director & Founder Managing Director & Founder Marketing Director Chairman & IR Manager INGEMAR KIHLSTRÖM BERNSTEN, ANNA MALM ALFHEIM, INGRID SKARBØVIK, MARIE BUCHMANN Deputy chairman Boardmember Boardmember Boardmember

14 Opportunities Our focus Early detection of Alzheimer s disease Early detection of breast cancer

15 Possible product candidates - Breast Cancer Planning/sample collection Discovery phase Prototype dev. Adjuvant test for breast cancer detection BC detection in familial high risk women BC detection in younger women Screening test for BC

16 The potential market Volume of targeted market segments for DiaGenic s breast cancer assay. Market Segments Adjuvant test to diagnostic mammography High risk families (3x incidence) Monitoring / follow-up of women with disease Screening Volume, Number of Tests/Y 2-3,000,000 tests 1,800,000 tests >2,000,000 tests > 150 mill. tests The figures represent potential volume of targeted segments in Europe, US and Japan Initial segments Intermediate and long term segments

17 Prices Commonly used technologies in breast cancer diagnosis (US) Screening mammography Ultrasound MRI PET Biopsy Genetic tests USD USD Approx. 220 USD Approx USD USD USD Sources: Genetichealth,

18 Possible product candidates ND Planning/sample collection Discovery phase Prototype dev. Adjuvant test for Neurodegenerative Disorders detection Early detection of ND Differential diagnosis of dementia Detection of other neurological disorders

19 Alzheimer s disease and cost for society Alzheimer s disease is the most costly disease for our society, 28 million people suffer from it and the direct-care cost is estimated to be 156 billion USD annually. This is more than both cardiovascular disease and cancer put together Bengt Winblad, June 2005

20 Alzheimers results and Award public funding Results from large project on ABI micro-array platform confirms pilot study 2H 2005: Industrial and scientific acceptance of concept January 2006: Public funding NOK 9,76 million over the years Important recognition from international panel of experts: A brilliant idea for development of early diagnostics Leading edge research Product with huge market potential Early detection of Alzheimer s disease beneficial for society

21 Alzheimer s disease therapeutic approach Current treatment: No known therapeutics will cure the disease. They only stabilise the symptoms associated with the disease. Early diagnosis and treatment may, however, delay the cognitive decline and thereby delay hospitalisation and improve quality of life. In the pipeline: Several drugs are in the pipeline that may stop the progression of the disease. Many of then aimed at blocking the effects of beta-amyloid Administer of antibodies against beta-amyloid Block enzyme (secretase inhibitors) that produce beta-amyloid Block accumulation of beta-amyloid

22 Highlights 4th Quarter 2005 Successful study on the test for Alzheimer s disease confirms results from pilot study Discussions with BioMerieux continued Grants from FUGE for the Alzheimer s disease project Average monthly burn rate 2005: NOK 1,5 mill (according to budget) Net cash position Jan 2006: NOK 12,5 mill

23 Outlook Increased visibility and recognition of the potential of our concept has lead to increased interest from IVD companies Industrial negotiations with biomérieux continues DiaGenic is on the radar screen of leading IVD companies Milestones 2006/2007: Commercial agreements on AD/BC First product prototypes to be developed by end 2006 Active patent strategy

1st. Quarter 2008 Presentation

1st. Quarter 2008 Presentation Erik Christensen MD PhD Chief Executive Officer Ruben Ekbråten Financial Controller 1 st Quarter Highlights New Patents Accepted on Alzheimer s Disease for Europe Patient